Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

tanezumab

Drug solution given intravenously only once at dose of 10 mg

BIOLOGICAL

tanezumab

Drug solution given subcutaneously only once at dose of 5 mg.

BIOLOGICAL

tanezumab

Drug solution given subcutaneously only once at dose of 10 mg.

BIOLOGICAL

tanezumab

Drug solution given subcutaneously only once at dose of 19 mg.

Trial Locations (1)

90630

Pfizer Investigational Site, Cypress

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY